Resverlogix Corp T.RVX

RVX-Reducing Cytokine Storms-Short List

[G1945V]

A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

Medicine in Drug Discovery Publication Explores Combination Protein Therapeutics, Including BET Inhibitors, in Preventing Severe Organ Damage from COVID-19 and Reviews Potential Treatments

CALGARY, Alberta, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its late-stage clinical candidate, apabetalone, has been prominently featured in a recent article, titled: “Protein-driven mechanism of multiorgan damage in COVID-19”, in the peer-reviewed journal Medicine in Drug Discovery.

The publication can be viewed using the following LINK.

“Significantly, this is the second peer-reviewed article to highlight apabetalone, the link between BET proteins – the exact target of apabetalone – and COVID-19,” said Donald McCaffrey, President and CEO of Resverlogix. “Of the many therapies discussed in the article, apabetalone is highlighted as a potential treatment for multiorgan damage caused by COVID-19 due to its safety profile and target. The publication suggests the case for apabetalone as a safe, potential COVID-19 therapeutic. We look forward to providing additional data on the effects of apabetalone on COVID-19 infection in our upcoming American Heart Association presentation on November 13, 2020.”

Publication Highlights and Discussions Include:

• The two most frequently mentioned causes of multiorgan damage produced by SARS-CoV-2 (known as COVID-19) are: (i) the direct viral toxicity and (ii) cytokine-release syndrome, or cytokine storm, leading to multiorgan damage
• SARS-CoV-2 (COVID-19) damage has been found to involve several organs / systems, such as neurologic, renal, hepatic, gastrointestinal, hematologic, cardiac, endocrine and dermatological, representing some key areas that apabetalone has already shown clinical benefits towards
• Among the key vulnerable proteins with roles in multiple organs and tissues were BET protein family members (key targets of apabetalone)
• As a direct inhibitor of BET proteins with the potential to beneficially impact inflammation, the authors propose apabetalone as a safe therapeutic with the high likelihood of efficacy against COVID-19

Program Update:

As previously announced, an article published on March 23, 2020 revealed the interaction between SARS-CoV-2 (COVID-19) protein E with BET proteins. Following this finding, Resverlogix put out a call for collaborations, resulting in multiple partnerships, and in parallel initiated preclinical research efforts in-house to further characterize and investigate apabetalone efficacy against COVID-19 infection. From our own studies we have found that beyond the role of BET proteins in viral replication, apabetalone was shown to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus to enter human cells. Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,000 subjects. Additional details from these multiple programs are expected to be presented in the coming few months.

G1945V

[snobei]

GV, im starting to drink the tvx covid coolaid. Maybe this covid chapter of our drug has legs. Glta longs

[G1945V]

If we're going to dream, let's dream big..haha! G1945V

[narmac]

,,,,,,even when we provide third party interesting data around covid we cant get interest in buying,,,,,there must be a fly in the ointment me thinks,,,,

[snobei]

Narmac im guessing ur a spot more knowledgeable on this stuff than i BUT, again, the only thing that will make the market accept our apology for missing these trial endpoints is meeting them or this panacea that is being promissed. Higher price mean less dilution when called for but we r range locked without the aforementioned. Tell bear i say hi and thx for the diligence. Lol

[priceless2]

Narmac,  I often wonder why RVX has not in a very very long time promoted the company to the mass media for the science potential in all areas of the science.   Is it nobody cares to know or won't listen, (being the media) what potential apabetalone has as a treatment for COVID 19,  Maybe RVX does not have the connections to get the message out to the masses....   

[narmac]

,,,,aaaaccchhhh,,its me just showing frustration here,,,appologies to the board,,, I have no idea why we are range bound,,,it is not normal imo,.,,,,,,I have been investing and watching the market for about 30 years or more and I have never known any play with such potential randomly trade sideways to down or at such levels before a serious news event,,especially when the news is expected to be

[fuzzyjr]

summed it well narmac, maybe were one those biotech's that ho hums along with the pathetic volume ,under valued SP & flat lining , then BOOM - double digits $$ & then hearing the media/public/friends etc - I didn't even know about this stock or wish I would of got in. It's happened before & it will happen again - maybe we're on this short list too 

[fuzzyjr]

so much potential - really could be a "star factory" & hopefully behind the scenes things are a brewing in a positive manner.Another bonus - nothing better than a Drug that says 'SAFE" at the bottom of the label.